Newsletter | August 6, 2024

08.06.24 -- Discovering "Molecular Hallmarks" And "Master Regulators" In Epilepsy

FEATURED EDITORIAL

Discovering "Molecular Hallmarks" And "Master Regulators" In Epilepsy

By Christian Wolff, UCB

As we look into the future, understanding the molecular hallmarks of epilepsies will be vital, and insights into the genetics and disease pathways will play a key role. The expert also discusses some of UCB's work in this area.

INDUSTRY INSIGHTS

New Biologic Drugs: Regulatory Challenges And Considerations

Article | By Parrish Galliher and Brian Hubbard, Cytiva

Along the drug candidate development journey there are many regulatory milestones and hurdles. Here are some tips to assist with up-front planning to alleviate headaches down the road.

Manufacturing Dry Powder Inhaled Formulations By Spray Drying

Q&A | Lonza

Kimberly Shepard, Ph.D., principal engineer in R&D, addresses the challenges associated with spray-drying late-stage lung cancer treatments, including proteins, peptides, and mAbs.

How Drug Delivery Is Enabling A Clinical Trial For Glioblastoma

Webinar | Nanoform

Discover highly promising in-vivo data, enabled by a nanoformed drug product for the treatment of glioblastoma multiforme (GBM).

A Hybrid Modeling Approach To Accelerate Media And Feed Development

Application Note | By Timo Schmidberger, Chloe Lang, et al., Sartorius

Explore the outcomes of a study focusing on building a mechanistic model to determine the growth kinetics of a CHO-based process producing a mAb.

Process Re-Design For Sustainability In Small Molecule Manufacturing

Webinar | Lonza

Review the optimization of the manufacturing process of a pharmaceutical intermediate, and discover how yield can be improved substantially via suitable reaction engineering.

Adapting To Change – API Custom Development And Manufacturing

Case Study | Cambrex

A pharmaceutical company sought a development and manufacturing partner to assist with an in-licensed product originating from an emerging pharma company, a molecule in clinical Phase II / III trials.